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Purpose: Our study is performed to find out clinicopathlogic and immunohisto-
chemical (IHC) characteristics of triple negative invasive lobular carcinoma (ILC), 
as has been demonstrated in their invasive ductal counterparts. Materials and 
Methods: Retrospective analysis of variable clinicopathlogic parameters and IHC 
stains for androgen receptor, estrogen receptor, progesterone receptor, p53, c-kit, 
galectin-3, cytokeratin 5 (CK5), CK5/6, vimentin, E-cadherin, epidermal growth 
factor receptor, and HER2 were performed in 117 cases of ILC. Results: Eight 
cases (6.8%) were triple negative carcinoma (TNC), which showed higher inci-
dence of high histologic grade than non-TNC (p = 0.019). Galectin-3 was expressed 
with higher incidence in tumor cells of TNC (62.5%) than those of non-TNC (7.3%) 
(p = 0.000). In contrast, galectin-3 was expressed with higher incidence in stromal 
cells of non-TNC (53.2%) than those of TNC (12.5%) (p = 0.029). CK5 and CK5/6 
were not expressed in all ILCs. Conclusion: TNC in ILC showed distinct clinico-
pathologic and IHC characteristics such as higher histologic grade and increased 
expression of galectin-3, compared to non-TNC in ILC. TNC in ILC was less fre-
quent and did not show CK5 and CK5/6 expression when compared to TNC in in-
vasive ductal carcinoma.
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INTRODUCTION
Invasive lobular carcinoma (ILC) is a distinctive subtype of invasive breast carci-
noma and comprise about 5-15% of all carcinoma of the breast.1,2 Substantial stud-
ies have shown that ILC has a distinctive characteristic that differs from invasive 
ductal carcinoma (IDC) not only in histologic and clinical characteristics,3,4 but 
also in gene analysis profile,5 immunophenotype3,6-8 and response to systemic ther-
apy.6-8 ILC demonstrates high incidence of older age, larger tumor size, low histo-
logic grade, less lymphatic invasion, loss of E-cadherin expression and frequently 
expression of hormone receptors.2 ILC shows a high rate of bilateral disease, mul-
tiple metastasis and unique patterns of metastasis compared with IDC.4,9,10 
In gene expression profiling analysis, breast cancer has been classified into lumi-
nal A, luminal B, HER2 overexpressiong, normal breast-like, and basal-like type.11 
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those seen in classic type ILC. The histological grade was 
assessed using Nottingham grading system,25 and nuclear 
grade was evaluated according to modified Black’s nuclear 
grade (1 = low grade, 2 = intermediate grade, and 3 = high 
grade).26 Histologic parameters were evaluated from the 
H&E-stained slides. Clinicopathologic parameters evaluated 
in each tumor included patient’s age at initial diagnosis, 
lymph node status, histological subtype, histologic grade, 
nuclear grade, tumor recurrence, time to recurrence, distant 
metastasis, and survival time. 
　
Tissue microarray
On the H&E-stained slide of the tumor, a representative 
area was selected and corresponding spot was marked on 
the surface of the paraffin block. Using a biopsy needle, the 
selected area was punched out and the 3 mm tissue core 
was placed in a 5 × 6 recipient block. At least, more than 
two tissue cores were extracted to minimize extraction bias. 
Each separate tissue core was assigned with a unique tissue 
microarray location number that was linked to database in-
cluding other clinical-pathologic data.
　
Immunohistochemistry
The antibodies used for immunohistochemistry in this study 
are shown in Table 1. All immunostainings were performed 
using formalin-fixed, paraffin-embedded tissue sections. 5 
μm thick sections were obtained with a microtome, trans-
ferred into adhesive slides, and dried at 62°C for 30 min. 
After incubation with primary antibodies, immunodetection 
was performed with biotinylated antimouse immunoglobu-
lin, followed by peroxidase-labeled streptavidin using a la-
beled streptavidin biotin kit with 3,3’-diaminobenzidine 
chromogen as substrate. Optimal incubation time and con-
centration of the primary antibody were determined via se-
rial dilution for each IHC assay with an identically fixed 
and embedded tissue block. Slides were counterstained 
with Harris hematoxylin. The staining was interpreted by 
two pathologists on a multiview microscope. 
All IHC markers were assessed by light microscopy. 
Scoring of immunostained slides was done according to the 
percentage of tumor cells exhibiting nuclear [androgen re-
ceptor (AR), ER, PR, and p53], nuclear and cytoplasmic (c-
kit, galectin-3), cytoplasmic (CK5, CK5/6, and vimentin), 
and membrane [E-cadherin, epidermal growth factor recep-
tor (EGFR), and HER2] staining. The ER and PR immuno-
histochemistry was scored using the so-called ‘Allred 
Score’.27 Briefly, a proportion score was assigned, repre-
About 80-90% of triple negative carcinoma (TNC) overlaps 
with basal-like breast cancer (BLBC) according to DNA 
microarray and immunohistochemical (IHC) study and 
have clinical behavior similar to BLBC.12 TNC has no ef-
fective modalities because of TNC is estrogen receptor 
(ER) and progesterone receptor (PR) negative for hormone 
treatment, and HER2 negative for trastuzumab treatment. 
TNC (ER-, PR-, HER2-) was used as a surrogate for BLBC 
because most BLBC did not express ER, PR, and HER2 
and it has the advantage that those three stains have already 
been used routinely in clinical work-up of breast cancer.13,14 
However, the overlap between BLBC and TNC is not com-
plete.15 BLBC classified by microarray DNA has revealed 
that 15-54% of them express at least one of three mark-
ers.14,16-19 In addition, TNC encompasses another molecular 
subgroup, namely normal-like breast cancer which has been 
shown to have slightly better prognosis than BLBC11,19 and 
to demonstrate no response to neoadjuvant chemotherapy.18
Most of previous studies on BLBCs have been performed 
on data sets and were predominantly composed of IDC. As 
least 85% of the cases from which the intrinsic gene set was 
derived was ductal type carcinoma.11,19-21 Although previous 
reports have shown that small subsets of ILC express basal 
cytokeratins (CKs),22-24 there have been no studies that sys-
tematically evaluated the incidence and significance of the 
TNC in ILC.
The purpose of our study is to investigate clinicopatho-
logic and IHC characteristics of TNC in ILC.  
MATERIALS AND METHODS
Patient selection and analysis of clinicopathologic 
parameters
From the files of the Department of Pathology in Severance 
Hospital, tissue samples from female patients with ILC 
were retrieved. The study was approved by the Institutional 
Review Board. All patients were diagnosed as having ILC 
by pathologists. All tissues were fixed in 10% buffered for-
malin and embedded in paraffin. All archival hematoxylin 
and eosin (H&E)-stained slides for each case were reviewed 
by 2 pathologists (Koo JS and Jung WH). Cases of mixed 
invasive lobular and ductal carcinoma were excluded. ILC 
of classic type was defined as small, relatively uniform carci-
noma cells which invaded the stroma singly and in a single 
file pattern. And ILC of pleomorphic type was defined as car-
cinoma cells with larger and more nuclear variation than 
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in xylene, and subsequently rehydrated in ethanol. After-
ward, they were boiled for 10 min in pre-treatment solu-
tion, incubated with pepsin solution for 10 min, dehydrated 
in ethanol for 6 min, and finally air-dried. For hybridiza-
tion, the buffered probe (HER2/neu and centromere 17) 
was brought onto the slide and protected by a coverslip that 
was sealed with rubber cement. For denaturation, slides 
were heated to 82°C and incubated overnight at 45°C in a 
dark humidified chamber. The rubber cement and coverslip 
were then removed, and the slides were transferred to strin-
gent wash buffer for 10 min at 65°C. Afterward, they were 
dehydrated in ethanol for 6 min and air-dried. Finally, 
counterstaining was performed with 4’,6-diamidino-2-phe-
nylindole (DAPI). Counterstained slide was examined with 
an epifluorescence microscope (Olympus, Tokyo, Japan) 
equipped with a fluorescein, Cy3, DAPI filter set and 100 
W mercury lamp. According to the Vysis manual (HER2 
gene appears as orange and centromere 17 as green), the 
number of HER2 gene and centromere 17 were countered. 
We counted signals in at least 20 tumor nuclei in 2 separate 
regions of the tissue section. As proposed by the ASCO/
CAP guideline,28 an absolute HER2 gene copy number 
lower than 4 or HER2 gene/chromosome 17 copy number 
ratio (HER2/Chr17 ratio) of less than 1.8 was considered 
HER2 negative; an absolute HER2 copy number between 
4 and 6 or HER2/Chr17 ratio between 1.8 and 2.2 was con-
sidered HER2 equivocal; and an absolute HER2 copy 
number greater than 6 or HER2/Chr17 ratio higher than 2.2 
was considered HER2 positive. Lymphocytes, fibroblasts, 
and normal ductal epithelial cells were used as internal 
controls. 
senting the estimated proportion of positive staining tumor 
cells (0 = none; 1 < 1/100; 2 = 1/100 to < 1/10; 3 = 1/10 to 
< 1/3; 4 = 1/3-2/3; 5 = > 2/3). Average estimated intensity 
of staining in positive cells was assigned with an intensity 
score (0 = none; 1 = weak; 2 = intermediate; 3 = strong). 
Proportion score and intensity score were added to obtain a 
total score that ranged from 0-8. The score of 0 to 2 was 
considered negative, and the score of 3 to 8 was considered 
positive. HER2 staining was scored according to the Ameri-
can Society of Clinical Oncology (ASCO)/College of Ameri-
can Pathologists (CAP) guideline28 using the following cat-
egories: 0, no immunostaining; 1+, weak incomplete mem-
branous staining, less than 10% of tumor cells; 2+, complete 
membranous staining, either uniform or weak in at least 10% 
of tumor cells; and 3+, uniform intense membranous stain-
ing in at least 30% of tumor cells. The case showing 2+ HER-
2 IHC staining was evaluated by fluorescent in situ hybrid-
ization (FISH) to measure HER2 amplification. The result 
of E-cadherin was classified into total loss and partial loss. 
Total loss was defined as no immunostaining in tumor cells 
and partial loss was defined as incomplete weak membra-
nous immunostaining. The IHC stain results of AR, p53, c-
kit, CK5, CK5/6, vimentin, galectin-3 and EGFR were con-
sidered positive when more than 10% tumor cell were 
stained.
FISH
FISH analysis (Vysis pathvision c-erbB2 probe + DAKO 
FISH histology accessory kit) was performed manually. In 
brief, sections from formalin-fixed, paraffin-embedded tis-
sue were mounted on Superfrost Plus slides, deparaffinized 
Table 1. Clone, Dilution, and Source of Antibodies Used
Antibody Clone Dilution Source
ER 6FH 1 : 100 Novocastra, UK
PR 1A6 1 : 200 Novocastra, UK
AR AR441 1 : 100 Lab Vision Corp.
HER2 c-erbB-2 1 : 100 DAKO, Denmark
CK5 XM26 1 : 100 Novocastra, UK
E-cadherin 36B5 1 : 100 Novocastra, UK
p53 DO-7 1 : 100 Novocastra, UK
EGFR EGFR.25 1 : 50 Novocastra, UK
Galectin-3 9C4 1 : 200 Novocastra, UK
c-kit Polyclonal 1 : 100 DAKO, Denmark
Vimentin V9 1 : 150 DAKO, Denmark
CK5/6 D5/16 B4 1 : 100 DAKO, Denmark
ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; CK, cytokeratin; EGFR, epidermal growth factor receptor.
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When the study group was classified according to the IHC 
stain results of ER, PR and HER2, 8 (6.8%) cases were 
TNC. Clinicopathologic characteristics between triple neg-
ative and non-TNC are compared in Table 2. Histologic 
grade of TNC was higher than that of non-TNC (p = 
0.019). There was a trend that nuclear grade of TNC was 
higher than that of non-TNC (p = 0.061). In histologic sub-
type, 1 (12.5%) case of pleomorphic type was TNC, and 7 
(6.4%) cases of classic type were TNC, revealing that pleo-
morphic type showed higher proportion to be TNC than 
classic type although this difference did not reach statistical 
significance (p = 0.511). There was no statistical significance 
in age, lymph node metastasis, tumor recurrence, and distant 
metastasis between TNC and non-TNC. 
We evaluated whether there was a prognostic difference 
between TNC and non-TNC group in ILC cases. In univar-
iate analyses, there was no statistically significant difference 
in disease-free survival and overall survival (p = 0.982, and 
0.424, respectively) (Fig. 1). 
　
IHC stain results
Table 3 demonstrates IHC characteristics of TNC (Fig. 2) 
and non-TNC (Fig. 3) in ILC. Galectin-3 was expressed 
with higher incidence in tumor cells of TNC (62.5%) than 
Statistical analysis   
Data were statistically processed using SPSS for Window 
version 12.0 (SPSS Inc., Chicago, IL, USA). For compari-
son of the groups, Student’s t and Fisher’s exact tests were 
used for continuous and categorical variables, respectively. 
Statistical significance was assumed when p < 0.05. Kaplan-
Meier survival curves and log-rank statistics were employed 
to evaluate disease-free survival and overall survival.
 
RESULTS
Clinicopathologic characteristics of patients
Table 2 shows clinicopathologic characteristics of 117 cas-
es of ILC. All patients were women with a mean age of 
50.14 ± 9.07 years (range, 35-81 years). One hundred nine 
(93.2%) cases were classic type and 8 (6.8%) cases were 
pleomorphic type. Histologic grade was scored as follows: 
grade I, 46 (39.3%) cases, grade II, 68 (58.1%) cases; and 
grade III, 3 (2.6%) cases. The number of cases of nuclear 
grade 1 was 46 (39.3%), nuclear grade 2 was 63 (53.8%), 
and nuclear grade 3 was 8 (6.9%). Thirty six (30.8%) cases 
showed axillary lymph node metastasis. Tumor recurrence 
and distant metastasis were noted in 13 (11.1%) cases. 
Table 2. Clinicopathologic Characteristics of Patients with Invasive Lobular Carcinoma
Parameter
Total 
(n = 117) (%)
Non-triple negative 
carcinoma
(n = 109) (%)
Triple negative 
carcinoma 
(n = 8) (%)
p value
Age (yr, mean ± SD) 50.14 ± 9.07 49.78 ± 8.78 55.00 ± 12.00 0.117
Histologic type 0.511
    Classic 109 (93.2) 102 (93.6) 7 (87.5)
    Pleomorphic     8 (6.8)     7 (6.4) 1 (12.5)
Histologic grade 0.019
    I   46 (39.3)   46 (42.2)
    II   68 (58.1)   61 (56.0) 7 (87.5)
    III     3 (2.6)     2 (1.8) 1 (12.5)
Nuclear grade 0.061
    1   46 (39.3)   46 (42.2)
    2   63 (53.8)   56 (51.4) 7 (87.5)
    3     8 (6.9)     7 (6.4) 1 (12.5)
Lymph node metastasis   36 (30.8)   34 (31.2) 2 (25.0) 0.642
Tumor recurrence   13 (11.1)   12 (11.0) 1 (12.5) 0.850
Distance metastasis   13 (11.1)   11 (10.1) 2 (25.0) 0.195
Disease related death     8 (6.8)     8 (7.3) 0 (0.0) 0.439
Duration of follow-up    
  (mos., mean ± SD)
53.24 ± 37.22 52.76 ± 37.28 60.14 ± 38.55 0.614
Triple Negative Lobular Carcinoma
Yonsei Med J   http://www.eymj.org   Volume 52   Number 1   January 2011 93
Fig. 1. Comparison of cumulative recurrence free survival (A) and cumulative overall survival (B) between TNC and non-TNC in ILC.  TNC, 
triple negative carcinoma; ILC, invasive lobular carcinoma. 
A
Table 3. Immunohistochemical Characteristics of Invasive Lobular Carcinoma
Immunohistochemical 
           markers
Total 
(n = 117) (%)
Non-triple negative 
carcinoma 
(n = 109) (%)
Triple negative 
carcinoma
(n = 8) (%)
p value
Galectin-3 (tumor cell) 0.000
    Positive   13 (11.1)     8 (7.3) 5 (62.5)
    Negative 104 (88.9) 101 (92.7) 3 (37.5)
Galectin-3 (stromal cell)
 Positive   59 (50.4)   58 (53.2) 1 (12.5) 0.029
 Negative   58 (49.6)   51 (46.8) 7 (87.5)
Androgen receptor 0.032
    Positive   58 (49.6)   57 (52.3) 1 (12.5)
    Negative   59 (50.4)   52 (47.7) 7 (87.5)
Vimentin 0.133
    Positive     2 (1.8)     1 (1.0) 1 (12.5)
    Negative 115 (98.2) 108 (99.0) 7 (87.5)
p53 0.496
    Positive     6 (5.1)     6 (5.5)
    Negative 111 (94.9) 103 (94.5) 8 (100)
CK5
    Negative 117 (100) 109 (100) 8 (100)
CK5/6
    Negative 117 (100) 109 (100) 8 (100)
EGFR 0.068
    Positive     1 (0.9) 1 (12.5)
    Negative 116 (99.1) 109 (100) 7 (87.5)
E-cadherin 0.411
    Total loss   97 (82.9)   91 (83.5) 6 (75.0)
    Partial loss   20 (17.1)   18 (16.5) 2 (25.0)
c-kit 0.644
    Positive   18 (15.4)   17 (15.6) 1 (12.5)
    Negative   99 (84.6)   92 (84.4) 7 (87.5)
HER-2 0.867
    Amplified     2 (1.7)     2 (1.8)
    Non-amplified 115 (98.3) 107 (98.2)   8 (100.0)
CK, cytokeratin; EGFR, epidermal growth factor receptor.
1.0
0.8
0.6
0.4
0.2
0.0
0 50 100 150
Months
Cu
m
ul
at
ive
 re
cu
rre
nc
e 
fre
e 
su
rv
iva
l
p = 0.982
TNC
Non-TNC
B
1.0
0.8
0.6
0.4
0.2
0.0
0 50 100 150
Months
Cu
m
ul
at
ive
 o
ve
ra
ll s
ur
viv
al
p = 0.424
TNC
Non-TNC
Ja Seung Koo and WooHee Jung
Yonsei Med J   http://www.eymj.org   Volume 52   Number 1   January 201194
(5.5%) cases of non-TNC. Total loss of E-cadherin was 
noted in 91 (83.5%) cases of non-TNC and 6 (75.0%) cases 
of TNC. And partial loss of E-cadherin was noted in 18 
(16.5%) cases of non-TNC and 2 (25.0%) cases of TNC (p 
= 0.411).
　
Relationship between galectin-3 expression and ER, 
PR, and HER2 expression
Table 4 shows correlation analysis between galectin-3 ex-
pression in tumor cells and ER, PR, and HER2 expression. 
Out of 13 cases with galectin-3 expression, 5 (38.5%) cases 
were ER negative and 8 (61.5%) cases were ER positive. 
those of non-TNC (7.3%) (p = 0.000). There were no dif-
ferences between nuclear and cytoplasmatic expression of 
galectin-3. However, there was a trend that cytoplasm ex-
pression was more predominant than nuclear expression. 
Galectin-3 was expressed with higher incidence in stromal 
cells of non-TNC (53.2%) than those of TNC (12.5%) (p = 
0.029). AR was expressed with higher incidence in non-
TNC (52.3%) than TNC (12.5%, p = 0.032). Vimentin, c-
kit and EGFR which are known as markers of BLBC were 
expressed in 1 (12.5%) case of TNC. And CK5 and CK5/6, 
another marker of basal-like carcinoma, was not expressed 
in either TNC or non-TNC. p53 was expressed in only 6 
Fig. 2. (A) Triple negative phenotype of invasive lobular carcinoma shows scattered tumor cells with abundant eosinophilic cytoplasm 
and hyperchromatic enlarged nuclei (× 200, H&E). (B) The tumor cells represent galectin-3 expression in cytoplasm (× 200, galectin-3).
A B
Fig. 3. (A) Non-triple negative phenotype of invasive lobular carcinoma shows linear strands of tumor cells in the fibrotic stroma (× 200, 
H&E). It expresses estrogen receptor (B) (× 200, ER) and progesterone receptor (C) (× 200, PR). (D) Peritumoral stromal cells demonstrate 
galectin-3 expresssion (× 200, galectin-3). ER, estrogen receptor; PR, progesterone receptor.
C
A
D
B
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kD protein of non-integrin β-galactoside-binding lectin 
family29 and its role is associated with cell adhesion, migra-
tion, cell growth, cell cycle regulation, apoptosis, and cellu-
lar repair process.30-33 Although the role of galectin-3 in car-
cinogenesis is not exactly known, it is reported to be related 
with tumor progression and metastasis in head and neck,33 
thyroid,34,35 gastric,30 and colon cancer.36 In breast cancer, 
galectin-3 showed down-regulation in IDC, but not in nor-
mal breast and benign disease.37 In addition, galectin-3 pre-
vents apoptosis caused by nitric oxide in breast cancer cells.38 
These results imply that galectin-3 is related with breast 
cancer development and progression. To our bestknowl-
edge, galectin-3 expression in ILC, has not been well inves-
tigated until now. Moisa, et al.39 reported that the nuclear 
staining for galectin-3 is more frequent in ILC than in IDC, 
and galectin-3 expression in breast cancer stroma is related 
to an unfavorable prognosis. Our results show that galec-
tin-3 is stained in both cytoplasm and nuclei, but more 
prominently in the cytoplasm, which is in concordance with 
the results reported by Moisa, et al. However, our study in-
volved only ILC, rendering the comparison with IDC im-
possible. Moreover, even though the stromal expression of 
galectin-3 is reported to be related to the poor prognosis, it 
is derived from the study, including both IDC and ILC, and 
thus its comparison with our results is not plausible. In our 
study, 88.9% of ILC were galectin-3 negative, which is 
slightly higher than that in IDC (40-74%) shown in previ-
ous study.37 When ILC was classified into TNC and non-
TNC, TNC showed significantly higher galectin-3 expres-
sion. In the present study, TNC showed higher incidence of 
high histologic grade (p = 0.016), and high nuclear grade (p 
= 0.061) than non-TNC, suggesting that TNC of ILC, as 
that of IDC, is a more aggressive histologic type. Paradoxi-
Out of 104 cases without galectin-3 expression, 4 (3.8%) 
cases were ER negative and 100 (96.2%) cases were ER 
positive. Therefore, higher incidence of ER negativity was 
noted in cases with galectin-3 expression (p = 0.001). In ad-
dition, higher incidence of PR negativity was noted in cases 
with galectin-3 expression (p = 0.039). There was no signif-
icant relationship between galectin-3 expression and HER-
2 expression (p = 0.730). 
DISCUSSION
　
Many researches have been ongoing since the concept of 
BLBC was raised through the gene expression profiling 
analysis of the breast cancer. Most of BLBC are reported to 
be ER, PR, and HER2 negative,12,14 rendering the entity to 
have the same clinical implication as TNC. However, the 
exact characteristics of TNC in ILC which comprise 5-15% 
of breast cancer are not so well-known because most of the 
previous intrinsic gene analysis were performed with at 
least 85% of ductal type carcinoma.11,19-21
In this study, 8 (6.8%) out of 117 cases of ILC were con-
firmed to be TNC through IHC and FISH. Generally, 15% 
of IDC are reported to be TNC,15 meaning that the propor-
tion of TNC is lower in ILC than in IDC. This difference in 
the proportion of TNC in ILC and IDC can be explained by 
the fact that ER and PR are somehow more frequently ex-
pressed in ILC than in IDC. 
This study also showed that the incidence of galectin-3 
expression is higher in the tumor cells of TNC than in those 
of non-TNC (p = 0.000). In contrast, galectin-3 was ex-
pressed with higher incidence in the stromal cells of non-
TNC than in those of TNC (p = 0.029). Galectin-3 is a 30 
Table 4. Relation between Galectin-3 Expression in Tumor Cells and ER, PR, and HER2 Expression
Immunohistochemical 
           markers
Galectin-3
p value
Negative (n = 104) (%) Positive (n = 13) (%)
Estrogen receptor 0.001
  Negative   4 (3.8) 5 (38.5)
  Positive 100 (96.2) 8 (61.5)
Progesterone receptor 0.039
  Negative   20 (19.2) 6 (46.2)
  Positive   84 (80.8) 7 (53.8)
HER2 0.730
  Non-overexpressed 102 (98.1) 13 (100.0)
  Overexpressed   2 (1.9)
ER, estrogen receptor; PR, progesterone receptor.
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logic and IHC characteristics, such as higher histologic 
grade, and increased expression of galectin-3, differing 
from non-TNC in ILC. TNC in ILC did not express CK5 
and CK5/6, in contrast to TNC in IDC. Further multi-insti-
tutional study on TNC in ILC should be performed with 
large number of cases in order to understand the biology of 
these tumors.     
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